On July 9th, Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. responded to investor inquiries via an interactive platform, stating the company is resolutely committed to positioning itself within the innovative drug sector.

By aligning with its own strategic plans and development capabilities, the firm continues to focus on cutting-edge directions in biotechnology research and development, striving to become a comprehensive pharmaceutical enterprise with capabilities in innovative drug R&D and clinical translation.

Should any merger, acquisition, or restructuring plans arise, they will be disclosed promptly in accordance with relevant regulations, including the Shanghai Stock Exchange Listing Rules.